How Sorafenib Tosylate Tablets Work
Sorafenib (Sorafenib) is considered to have a dual mechanism of action. It blocks tumor proliferation and growth by inhibiting theRAF/MEK/extracellular signal-regulated kinase (ERK) pathway on tumor cells, and reduces tumor angiogenesis by inhibiting VEGFR and PDGFR signaling in the tumor vasculature. Sorafenib remains recognized as a first-line systemic treatment for advanced hepatocellular carcinoma (HCC) despite only modest improvements in overall median survival.

Sorafenib is a molecularly targeted drug that acts on vascular endothelial growth factor receptors (VEGFR1, 2, 3), platelet-derived growth factor receptor-β (PDGFRβ) and Raf family kinases (mainly C-Raf rather than B-Raf). Two international randomized controlled trials (RCT) played a key role in the approval of sorafenib for the treatment of advanced HCC. Compared with the placebo group, the median overall survival of the sorafenib treatment group was extended by about3 months (10.7 vs. 7.9). Although the efficacy of sorafenib against placebo is limited, they all indicate that sorafenib is the standard treatment drug for the first-line treatment of patients with advanced HCC. They also show differential sensitivity to treatment in approximately 30% of patients, suggesting intrinsic or acquired resistance to the drug.
The original drug of sorafenib has been launched in China and has entered the scope of medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may vary. SpecificationsThe price of 0.2g*60 tablets may be around 1,200 yuan. The original drug of sorafenib has also been launched overseas, and there are also generic drugs of sorafenib produced in other countries. The price of 0.2g*60 tablets produced by a Bangladesh pharmaceutical factory is around RMB 450 (the price may fluctuate due to the exchange rate). The ingredients of the original drug are basically the same as those of the generic drugs. For specific prices and drug details, please consult the medical consultant of Yaode.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)